Acute Lymphoblastic Leukemia research

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups

This study identifies how developmental maturity and fusion partner influence treatment response in KMT2A-rearranged B-ALL across all ages.

Altered immune and treatment response gene expression signatures among poverty-exposed children with B-ALL

This study identifies transcriptional signatures of steroid resistance and altered immune responses in poverty-exposed children with B-ALL using single-cell RNA sequencing.

IKAROS Gene Regulatory Network Reveal ERG as a Vulnerability in B-cell Acute Lymphoblastic Leukemia

This study identifies ERG as a vulnerability in IKZF1-mutated B-cell acute lymphoblastic leukemia through gene regulatory network analysis and functional validation.

TASC: A transcriptome-driven machine learning classifier to explore molecular heterogeneity and relapse-associated programs in T-cell Acute Lymphoblastic Leukemia

This paper introduces a transcriptome-driven machine learning classifier to predict molecular subtypes in T-cell Acute Lymphoblastic Leukemia and reveals subtype-specific relapse patterns.

A comprehensive bulk and single-cell transcriptional atlas of pediatric leukemias

This study presents a comprehensive bulk and single-cell transcriptional dataset of 69 pediatric leukemia patients, demonstrating its utility in improving leukemia characterization and clinical testing.

PTEN-loss confers dependence on the guanylate synthesis enzyme IMPDH in T-cell acute lymphoblastic leukemia

This paper identifies IMPDH as a therapeutic target in PTEN-deficient T-ALL, showing IMPDH inhibitors selectively kill these cells and extend survival in mouse models.

Targeting glucocorticoid-induced CD20 activation in preclinical models of B-ALL

This study identifies CD20 as an actionable target in B-ALL MRD using PDX models and single-cell RNA sequencing, showing anti-CD20 antibodies can eradicate drug-resistant cells.

A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity

This paper identifies I3IN-002, a small molecule inhibitor of IGF2BP3, which shows anti-leukemic activity in cell lines and a mouse model.

Cell state transitions drive the evolution of disease progression in B-lymphoblastic leukemia

This paper develops a mathematical model of cell state transitions in B-ALL to correlate with BCR::ABL1 status, MRD, and relapse risk using flow cytometry data.

SKIDA1 transiently sustains MLL::ENL-Expressing hematopoietic progenitors during neonatal stages and promotes B-lineage priming

This study identifies SKIDA1 as a gene promoting B-lineage priming in neonatal MLL::ENL-expressing hematopoietic progenitors, with implications for age-specific leukemogenesis.

Phospho 394Y LCK flow-cytometry readout predicts dasatinib sensitivity in paediatric T-cell acute lymphoblastic leukaemia

The paper identifies phospho-LCK (pY394) as a biomarker for dasatinib sensitivity in paediatric T-ALL using flow-cytometry, showing strong correlation with drug response.

The impact of Indigenous American-like ancestry on risk of acute lymphoblastic leukemia in Hispanic/Latino children

This study investigates the impact of Indigenous American-like ancestry on acute lymphoblastic leukemia risk in Hispanic/Latino children, finding no global association but significant local haplotype effects.

Automatic computational classification of bone marrow cells for B cell pediatric leukemia using UMAP

The paper develops an AI algorithm using UMAP to classify bone marrow cells in B-ALL patients, improving disease prognosis and therapy decisions by identifying key subpopulations.

Identification of Novel Fusion Genes in Pediatric B-ALL patients Using Whole Transcriptome Sequencing

This study identifies 19 high-confidence fusion genes in 12 pediatric B-ALL patients using whole transcriptome sequencing, revealing novel and unreported fusion events.

Genomic Classification of Acute Lymphoblastic Leukemia Using AI: Towards Personalized Medicine

This study uses AI to classify acute lymphoblastic leukemia subtypes from gene expression data, improving diagnostic accuracy and enabling personalized treatment strategies.

Combined multi-color immunofluorescence staining and spatial in situ mRNA expression analysis identifies potential fibrosis drivers in acute lymphoblastic leukemia

The paper identifies TGFB1 and PDGFA1 as potential fibrosis drivers in pediatric ALL by combining spatial RNA and immunofluorescence analysis.

Differentiation hierarchy in adult B cell acute lymphoblastic leukemia at clonal resolution

This study uses barcoding and multiome single-cell data to show a unidirectional differentiation hierarchy in B-ALL with an immature population having high leukemogenic potential.

A three-dimensional ex vivo model recapitulates in vivo features and unravels increased drug resistance in childhood acute lymphoblastic leukemia

This paper develops a 3D ex vivo model of bone marrow to study childhood ALL, finding increased drug resistance in certain subtypes compared to 2D models.

Pre-TCR-Targeted Immunotherapy for T-cell Acute Lymphoblastic Leukemia

This study identifies the pre-TCR as a target for immunotherapy in T-ALL, showing that anti-pre-TCR antibodies inhibit leukemia-initiating cell activity and tumor progression in xenograft models.

Distinct Stromal Cell Populations Define the B-cell Acute Lymphoblastic Leukemia Microenvironment

This study identifies distinct stromal cell populations in B-ALL bone marrow and shows their roles in supporting leukemic cell survival and chemoresistance.

Comparative analysis of plasma and bone marrow nutrient levels in pediatric B-ALL patients

This study compares nutrient levels in plasma and bone marrow of pediatric B-ALL patients, identifying metabolic differences between subtypes and highlighting unique metabolic features in B-ALL circulation.

Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression between patients

This study identifies enhancer heterogeneity as a driver of transcriptional differences in KMT2A::AFF1 ALL patients, revealing patient-specific enhancer activity at oncogenes.

Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy

This study identifies BRG1 as a critical target in Ph-like B-ALL, showing its inhibition leads to cell cycle arrest and improved survival in preclinical models.

Role of Stem-Like Cells in Chemotherapy Resistance and Relapse in pediatric T Cell Acute Lymphoblastic Leukemia

This study identifies treatment-resistant stem-like T-ALL cells that expand during relapse using single-cell RNA sequencing of pediatric T-ALL patient samples.

Error reduction in leukemia machine learning classification with conformal prediction

This study applies conformal prediction to reduce false negative rates in leukemia subtype classification using RNA-seq data.

The STAMP inhibitor asciminib is a new treatment option for ABL-rearranged ALL revealing a novel role for the 5' fusion partner in determining drug response

This study shows asciminib effectively treats NUP214::ABL1 ALL in preclinical models by inhibiting ABL1 kinase and improving survival.

Linker histone H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape

This study identifies H1-0 as a mediator of ETV6::RUNX1-induced quiescence in BCP-ALL preleukemic cells and suggests HDACi treatment as a potential therapeutic approach.

Real-time genomic characterization of pediatric acute leukemia using adaptive sampling

This study demonstrates real-time genomic classification of pediatric acute leukemia using long-read sequencing with adaptive sampling, identifying key alterations faster than traditional methods.

Single-Cell Sequencing Reveals Extensive Genetic Diversity Underlying Pediatric ALL Treatment Complexity

The paper uses single-cell sequencing to uncover hidden genetic diversity in pediatric ALL that is not detected by bulk sequencing, identifying treatment-resistant clones and their associated mutations.

Harnessing ALDH1A2 vulnerability in T-cell acute lymphoblastic leukemia

This study identifies ALDH1A2 as a therapeutic target in T-ALL, showing its essential role in leukemic cell survival and demonstrating potent anti-leukemic activity with Dimate inhibition.